Mytreya Files New Patent for 'Anti-Aging' Composition
Key facts
- Mytreya Files New Patent for 'Anti-Aging' Composition
- Mytreya Co., Ltd. has filed a patent for an 'anti-aging composition' that uniquely combines NMN, exosomes, and allantoin. Developed in joint research with Miyazaki Prefecture and Tsutsumi Planning Co., Ltd., the composition utilizes the transdermal delivery technology 'nano PDS®' and has shown suppression of a senescence marker in tests.
- Source: PR Times
- Date: June 3, 2026
Direct answer
Mytreya Co., Ltd. has filed a patent for an 'anti-aging composition' that uniquely combines NMN, exosomes, and allantoin. Developed in joint research with Miyazaki Prefecture and Tsutsumi Planning Co., Ltd., the composition utilizes the transdermal delivery technology 'nano PDS®' and has shown suppression of a senescence marker in tests.
- Citation
- Mytreya Files New Patent for 'Anti-Aging' Composition (June 3, 2026), PR Times
- Source
- PR Times
- Date
- June 3, 2026
Mytreya Co., Ltd. has filed a patent for an 'anti-aging composition' that uniquely combines NMN, exosomes, and allantoin. Developed in joint research with Miyazaki Prefecture and Tsutsumi Planning Co., Ltd., the composition utilizes the transdermal delivery technology 'nano PDS®' and has shown suppression of a senescence marker in tests.
📋 Article Processing Timeline
- 📰 Published: June 3, 2026 at 10:00
- 🔍 Collected: June 3, 2026 at 10:28 (28 min after Published)
- 🤖 AI Analyzed: June 7, 2026 at 01:33 (87h 5m after Collected)
Unique Combination of NMN, Exosomes, and Allantoin
Mytreya Co., Ltd. (Headquarters: Osaka City, Osaka; Representative Director: Tadashi Inagaki) announces that it has filed a new patent application for an 'anti-aging composition' combining Nicotinamide Mononucleotide (NMN), exosomes, and allantoin, based on joint research with Miyazaki Prefecture and Tsutsumi Planning Co., Ltd.
In tests using normal human dermal fibroblasts, the composition was confirmed to suppress 'SA-β-gal activity,' a known marker of cellular senescence. This suggests an anti-aging effect of the composition.
Moving from 'Aging Care' to 'Anti-Aging'
Until now, the cosmetics industry has focused on 'firmness,' 'radiance,' and 'aging care.' In contrast, Mytreya has focused on 'anti-aging' itself.
The company has been advancing research on a new composition that uniquely combines NMN, exosomes, and allantoin to target cellular senescence markers. This patent application pertains to a unique composition aimed at 'anti-aging,' utilizing the transdermal delivery technology 'nano PDS®.'
An Era Where 'Penetration' Alone is Not Enough for Differentiation
nano PDS® is a penetration technology that has been used by multiple companies. Within this context, Mytreya focuses on 'what to deliver and how to deliver it.' By uniquely combining NMN, exosomes, and allantoin, the company aims to create a new differentiation area in 'anti-aging.'
Comment from Tadashi Inagaki, Representative Director of Mytreya Co., Ltd.
"We believe that in the future, cosmetics will not be able to differentiate themselves solely by 'penetration.' What matters is 'what to deliver and how to deliver it.' This time, we focused on the combination of NMN, exosomes, and allantoin to pursue the new possibility of 'anti-aging.' Moving forward, Mytreya will continue to refine its unique value, including research, formulation, and worldview."
What is nano PDS®?
nano PDS® (Particle Delivery System) is a transdermal delivery technology born from joint research with Miyazaki Prefecture. It is researched and developed with the aim of delivering even high-molecular-weight components, which have traditionally been difficult to penetrate, to the stratum corneum while maintaining their structural integrity.
Future Developments
Mytreya plans to utilize this patented technology for applications in:
・Anti-aging cosmetics
・Aging care field
・Medical aesthetics field
・Overseas expansion
Patent Overview
Invention Title:
"Anti-aging composition containing nicotinamide mononucleotide, exosomes, and allantoin, and method for producing the same"
Applicants:
Mytreya Co., Ltd. / Tsutsumi Planning Co., Ltd. / Miyazaki Prefecture
Filing Date:
May 14, 2026
Application Number:
Patent Application 2026-081378
Company Overview
Company Name: Mytreya Co., Ltd.
Representative: Representative Director Tadashi Inagaki
Location: 1-6-29-2702 Nakatsu, Kita-ku, Osaka City, Osaka
URL: https://mytreya.jp/
Contact for Inquiries
Mytreya Co., Ltd.
Public Relations, Nagai
Email: info@mytreya.jp
[Note]
This release contains information regarding research, development, and patent applications.
It is not intended to make claims that deviate from the efficacy and effects of cosmetics.
Mytreya Co., Ltd. (Headquarters: Osaka City, Osaka; Representative Director: Tadashi Inagaki) announces that it has filed a new patent application for an 'anti-aging composition' combining Nicotinamide Mononucleotide (NMN), exosomes, and allantoin, based on joint research with Miyazaki Prefecture and Tsutsumi Planning Co., Ltd.
In tests using normal human dermal fibroblasts, the composition was confirmed to suppress 'SA-β-gal activity,' a known marker of cellular senescence. This suggests an anti-aging effect of the composition.
Moving from 'Aging Care' to 'Anti-Aging'
Until now, the cosmetics industry has focused on 'firmness,' 'radiance,' and 'aging care.' In contrast, Mytreya has focused on 'anti-aging' itself.
The company has been advancing research on a new composition that uniquely combines NMN, exosomes, and allantoin to target cellular senescence markers. This patent application pertains to a unique composition aimed at 'anti-aging,' utilizing the transdermal delivery technology 'nano PDS®.'
An Era Where 'Penetration' Alone is Not Enough for Differentiation
nano PDS® is a penetration technology that has been used by multiple companies. Within this context, Mytreya focuses on 'what to deliver and how to deliver it.' By uniquely combining NMN, exosomes, and allantoin, the company aims to create a new differentiation area in 'anti-aging.'
Comment from Tadashi Inagaki, Representative Director of Mytreya Co., Ltd.
"We believe that in the future, cosmetics will not be able to differentiate themselves solely by 'penetration.' What matters is 'what to deliver and how to deliver it.' This time, we focused on the combination of NMN, exosomes, and allantoin to pursue the new possibility of 'anti-aging.' Moving forward, Mytreya will continue to refine its unique value, including research, formulation, and worldview."
What is nano PDS®?
nano PDS® (Particle Delivery System) is a transdermal delivery technology born from joint research with Miyazaki Prefecture. It is researched and developed with the aim of delivering even high-molecular-weight components, which have traditionally been difficult to penetrate, to the stratum corneum while maintaining their structural integrity.
Future Developments
Mytreya plans to utilize this patented technology for applications in:
・Anti-aging cosmetics
・Aging care field
・Medical aesthetics field
・Overseas expansion
Patent Overview
Invention Title:
"Anti-aging composition containing nicotinamide mononucleotide, exosomes, and allantoin, and method for producing the same"
Applicants:
Mytreya Co., Ltd. / Tsutsumi Planning Co., Ltd. / Miyazaki Prefecture
Filing Date:
May 14, 2026
Application Number:
Patent Application 2026-081378
Company Overview
Company Name: Mytreya Co., Ltd.
Representative: Representative Director Tadashi Inagaki
Location: 1-6-29-2702 Nakatsu, Kita-ku, Osaka City, Osaka
URL: https://mytreya.jp/
Contact for Inquiries
Mytreya Co., Ltd.
Public Relations, Nagai
Email: info@mytreya.jp
[Note]
This release contains information regarding research, development, and patent applications.
It is not intended to make claims that deviate from the efficacy and effects of cosmetics.
FAQ
What is the core technology of Mytreya's new patent?
It is the unique combination of NMN, exosomes, and allantoin, delivered via the transdermal technology 'nano PDS®'.
When was this patent filed?
May 14, 2026.
Who are the joint applicants for this patent?
Mytreya Co., Ltd., Tsutsumi Planning Co., Ltd., and Miyazaki Prefecture.